Department of Medicine, Cardiovascular Medicine Division, University of Virginia Health System, 1215 Lee Street, PO Box 800158, Charlottesville, VA, 22908, USA.
Department of Biomedical Engineering, University of Virginia Health System, Charlottesville, VA, USA.
J Nucl Cardiol. 2018 Dec;25(6):2148-2158. doi: 10.1007/s12350-018-1293-9. Epub 2018 May 7.
Cancer therapeutics-related cardiac dysfunction (CTRCD) is a well-established adverse effect resulting from a number of cancer therapeutics. Newer immunotherapy has been associated with cardiomyopathy and myocarditis making comprehensive imaging useful for early recognition. Cardiac MRI (CMR) offers a comprehensive evaluation to detect CTRCD. Established guidelines for monitoring left ventricular ejection fraction for potential cardiotoxicity have recently incorporated CMR. We will review the utility of CMR in contemporary evaluation for potential oncologic cardiotoxicity.
癌症治疗相关的心脏功能障碍（CTRCD）是许多癌症治疗方法所产生的一种公认的不良反应。新型免疫疗法与心肌病和心肌炎有关，因此全面的影像学检查对于早期识别很有用。心脏磁共振成像（CMR）可提供全面的评估以检测 CTRCD。最近，用于监测潜在心脏毒性的左心室射血分数的既定指南已纳入 CMR。我们将回顾 CMR 在潜在肿瘤性心脏毒性的当代评估中的应用。
